Posted 3/18/2024, 10:30:00 PM
AstraZeneca Caps Monthly Inhaler Costs at $35 in Response to Senate Scrutiny of High Prices
- AstraZeneca capping monthly out-of-pocket inhaler costs at $35 starting June 1st
- Move matches similar cap by competitor Boehringer Ingelheim
- Follows investigation by Senate committee into high US inhaler prices
- AstraZeneca congratulated by Sen. Bernie Sanders, who urges other companies to follow
- Advocacy group AAFA welcomes effort but says all health care stakeholders must address affordability
